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Abstract
Background: The change in epigenetic signatures, in particular DNA methylation, has been proposed as risk
markers for various age-related diseases. However, the course of variation in methylation levels with age, the
difference in methylation between genders, and methylation-disease association at the whole genome level is
unclear. In the present study, genome-wide methylation levels in DNA extracted from peripheral blood for 2116
healthy Chinese in the 2–97 age range and 280 autistic trios were examined using the fluorescence polarization-
based genome-wide DNA methylation quantification method developed by us.
Results: Genome-wide or global DNA methylation levels proceeded through multiple phases of variation with age,
consisting of a steady increase from age 2 to 25 (r = 0.382) and another rise from age 41 to 55 to reach a peak level
of ~80 % (r = 0.265), followed by a sharp decrease to ~40 % in the mid-1970s (age 56 to 75; r = −0.395) and leveling
off thereafter. Significant gender effect in methylation levels was observed only for the 41–55 age group in which
methylation in females was significantly higher than in males (p = 0.010). In addition, global methylation level was
significantly higher in autistic children than in age-matched healthy children (p < 0.001).
Conclusions: The multiphasic nature of changes in global methylation levels with age was delineated, and
investigation into the factors underlying this profile will be essential to a proper understanding of the aging process.
Furthermore, this first report of global hypermethylation in autistic children also illustrates the importance of age-
matched controls in characterization of disease-associated variations in DNA methylation.
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quantification
Background
Genetic changes can alter the genomic DNA sequence
through point mutations, insertions, deletions, copy num-
ber variations, and chromosomal rearrangements while
epigenetic modifications can modulate phenotype and
gene expressions. DNA methylation is the most common
epigenetic modification that plays an essential role in the
regulation of tissue-specific gene expression, cellular differ-
entiation, chromosome stabilization, genomic imprinting,
and suppression of transposable element mobility [1, 2].
DNA methylation through DNA methyltransferases con-
vert cytosine to 5-methycytocine, with the majority of the
conversions occurring at CpG islands found in gene pro-
moter regions. Aberrant DNA methylation patterns have
long been associated with various human diseases includ-
ing cancers, cardiovascular diseases, psychotic disorders,
and autism [3–6].
Changes in epigenetics signatures, and in particular
DNA methylation, have been reported to occur in nor-
mal physiological development and aging, and alter-
ations in DNA methylation associated with the signaling
and regulation of transcription have been demonstrated
in some genes [7, 8]. Aging is the gradual deterioration
of various body functions and represents an important
risk factor for various age-related diseases such as can-
cer, neurodegenerative disorders, cardiovascular diseases,
and type 2 diabetes mellitus [9]. Several studies have
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examined DNA methylation changes in old age as dis-
ease risk factor, focusing mostly on CpG islands and
promoter regions in specific gene [10, 11]. However, the
characterization of lifelong age-related changes in DNA
methylation at the whole genome level has remained a
largely unexplored area.
During the past decades, various HPLC-based,
sequencing-based, (e.g., bisulfite-sequencing and methyl-
ated DNA immunoprecipitation) and microarray-based
methods have been introduced to quantitate genomic
DNA methylation [12]. Although these methods enable
high-resolution and detailed methylation profiles of indi-
vidual genes, they are time-consuming and incapable of
measuring whole genome methylation levels accurately.
Recently, a number of methods have been developed to
render possible the measurement of whole genome methy-
lation levels, including the LUminometric Methylation
Assay (LUMA) method [13], the ELISA-based approach
[14], and the fluorescence polarization DNA methylation
(FPDM) method developed by us [15].
The objective of the present study was to analyze
whole genome DNA methylation in the normal popula-
tion in order to establish the quantitative relationship
between global DNA methylation levels and age using the
simple and accurate FPDM method, as well as delineate
any gender differences. The DNA methylation-aging curve
obtained for the normal population will provide a useful
reference to facilitate an improved understanding of the
regulation of DNA methylation in aging. Moreover, autism-
associated changes in genome-wide methylation were
investigated, which also served to demonstrate the import-




The main study population in this study were enrolled
from Beijing, Shanghai, Changsha, and Hong Kong and
consisted of 2116 healthy Chinese subjects including
1108 (52.36 %) males and 1008 (47.64 %) females. The
subjects spanned a wide age range from 2 to 97 years.
The 280 autistic children (age 2-13 years) and their par-
ents (n = 552; age 24–62 years) were recruited at Central
South University in Changsha. Samples from the parents
but not those from the children were included in the
main study set for age-methylation analysis.
Genomic DNA extraction
Leukocytes were isolated from 5-ml peripheral blood
samples. DNA was prepared by phenol extraction and
chloroform extraction followed by isopropanol precipita-
tion, washed with ethanol, and air-dried. Tris-EDTA
buffer pH 8.0 was used to dissolve the final genomic
DNA product.
Whole genome DNA methylation analysis by FPDM
To determine genome-wide or “global” DNA methylation
by fluorescence polarization DNA methylation measure-
ment, ~100 ng DNA sample was first subjected to separate
restriction-enzyme digestions by HpaII and MspI as
described [15]; the methylation-sensitive HpaII cut only
un-methylated 5′CCGG-3′ sites, whereas the methylation-
insensitive MspI cut both methylated and un-methylated
5′-CCGG-3′ sites. After completion of the restriction reac-
tions, both digests were subjected to a one-label-extension
reaction through incubation with fluorescent TAMRA-
dCTP (5-propargylamino-dCTP-5/6-carboxytetra-methylr-
hodamine, Jena Bioscience) and Taq DNA polymerase.
Measurements of fluorescence polarization on the two di-
gests following the extension reaction yielded the percent-
ile global methylation in the DNA sample. The global
DNA methylation level in each instance was thus expressed
in terms of the global percentage of CpG sites in genomic
DNA that were methylated based on the average of tripli-
cate measurements.
Statistical data analysis
Statistical analysis of data was performed using SPSS
19.0. Percentile methylation of each DNA sample repre-
sented the average of three independent measurements.
To assess the relationship between global DNA methyla-
tion and age, methylation levels of samples in every 5-
year age range were first analyzed for correlation with age
using Pearson’s correlation test. Based on these results,
the samples were further grouped into five age ranges to
represent different phases of methylation change with age
and again analyzed using Pearson’s correlation to yield an
overall correlation coefficient for each age range. Differ-
ences in methylation levels between males and females
were analyzed for all samples using independent sample t
test as well as for each group of samples in the five age
ranges using multivariable linear regression. Independent
sample t test was used to analyze the methylation differ-
ence between autistic children and parents and be-
tween autistic children and age-matched healthy children.
A p value <0.05 was regarded as statistically significant.
Results
The methylation data is given in Additional file 1: Table S1.
Although the global DNA methylation data determined
using the FPDM method displayed large standard devia-
tions, when the subjects were divided into 5-year age
groups and analyzed for within-group correlations with age,
positive correlations were detected in the 16–20 and 51–55
groups, and a negative correlation was detected in the 56–
60 group (Table 1). Based on the within-group correlations
and the methylation-age plot (Fig. 1), multiple phases of
change in methylation levels with age were discerned in-
cluding a steady increase from year 2 to year 25 and
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another rise from year 40 onward to reach a peak level at
year 55, followed by a sharp decrease up to year 75 and
leveling off thereafter. Quantitatively, the increase from
age 2 up to the age of 25 was significant to p < 0.001 with
Pearson’s correlation coefficient r = 0.382. From 26 to
40 years of age, there was no significant change in
methylation (r = 0.028; p = 0.459). However, the DNA
methylation levels again significantly increased with age
between 41 to 55 years (r = 0.265; p < 0.001). From 56 to
75 years of age, there was a significant decrease in global
DNA methylation (r = −0.395; p < 0.001) showing an in-
verse relationship between methylation and age, and no
significant change in methylation levels was observed be-
tween 75 and 97 years of age (r = −0.061; p = 0.486). The
correlation data for these different age groups are given in
Additional file 2: Table S2.
With respect to the genders (Table 2), a statistically
significant gender effect was observed in the 41 to 55
age group (beta = 0.136; p = 0.010), where the average
methylation levels in males (73.49 ± 15.26) was higher
than that in females (77.52 ± 13.44). There was no sig-
nificant gender effect in any of the other age groups or
when all age groups were combined.
The global methylation levels for autistic children
(n = 280; mean age = 4.7) were compared to both those of
their healthy parents (n = 552; mean age = 33.8) and those
of age-matched healthy children (n = 236; mean age = 5.3).
No significant difference (p = 0.872) was observed between
patients (65.18 ± 16.69) and parents (66.01 ± 19.98)
(Additional file 3: Table S3); but the difference between pa-
tients and age-matched controls (54.35 ± 21.37) was highly
significant (p < 0.001), with increased methylation in the pa-
tients (Fig. 2). There was no significant difference in methy-
lation between autistic children and either their fathers or
mothers separately (Additional file 3: Table S3).
Discussion
The purpose of the present study has been to analyze,
using the FPDM method, the global DNA methylation
Table 1 Global DNA methylation levels of different age groups
Age range Number Global DNA methylation
(%, mean ± SD)
Pearson’s ra p valueb
1–5 160 47.52 ± 17.51 0.040 0.614
6–10 93 49.41 ± 17.03 0.053 0.613
11–15 68 54.73 ± 16.69 0.055 0.658
16–20 207 60.10 ± 17.78 0.205 0.003
21–25 100 66.92 ± 17.78 0.029 0.775
26–30 188 54.11 ± 16.10 0.008 0.916
31–35 321 66.68 ± 17.95 −0.059 0.292
36–40 202 68.24 ± 15.96 0.127 0.073
41–45 112 71.09 ± 16.08 0.150 0.113
46–50 129 77.17 ± 14.13 0.138 0.120
51–55 92 79.22 ± 10.95 0.213 0.041
56–60 68 69.84 ± 20.02 −0.294 0.015
61–65 120 53.20 ± 22.13 −0.028 0.765
66–70 71 51.54 ± 24.41 −0.061 0.612
71–75 54 39.13 ± 17.18 −0.133 0.339
76–80 75 54.73 ± 16.69 −0.064 0.584
81–85 36 40.95 ± 15.27 −0.023 0.896
>85 20 39.78 ± 12.08 −0.073 0.758
aPearson’s correlation coefficients pertaining to within-group analysis
bp values less than 0.05 are shown in italic font
Fig. 1 Variation of global DNA methylation with age. Mean global
DNA methylation of 5-year age groups are shown. Error bars indicate
the standard errors of the mean, and the three arrows represent (a)
increasing trend at age range 1–25 years, (b) increasing trend at age
range 40–55 years, and (c) decreasing trend at age range 55–75 years.
The two dashed lines indicate the two age ranges (25–40 and over
75 years) where there were no significant changes in methylation
Table 2 Global DNA methylation levels in different male and
female age groups
Age groups Gender Number Global DNA methylation
(%, mean ± SD)
p valuea
2–25 Male 414 54.99 ± 18.70 0.370
Female 214 57.42 ± 18.92
26–40 Male 356 67.17 ± 16.56 0.816
Female 355 67.31 ± 17.29
41–55 Male 151 73.49 ± 15.26 0.010
Female 182 77.52 ± 13.44
56–75 Male 127 56.42 ± 23.34 0.152
Female 186 52.37 ± 23.50
75–97 Male 60 40.72 ± 14.14 0.711
Female 71 41.46 ± 14.20
Overall Male 1108 60.81 ± 19.86 0.060b
Female 1008 62.47 ± 20.81
p < 0.05 is shown in italic font
ap values using gender as a variable in multivariable linear regression analyses
bp value for between-gender comparison using Student’s t test
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levels in leukocytes as a function of age in order to establish
a continuous methylation-age curve for the population that
could serve as a basis for describing phenotypic changes as-
sociated with aging and as an age-dependent standard for
the detection of any significant deviation caused by disease.
In providing a systematic characterization of the depend-
ence of global DNA methylation on age, the study revealed
that global DNA methylation as a genomic parameter of
age was distinctly multiphasic in character. The global
DNA methylation-age curve displayed evident increases
over the adolescent age group of 10–20 and late middle-
age age group of 40–50 and a sharp decrease over the age
group of 55–70 to reach a hypomethylation level from age
71 onwards as a hallmark of old age. Previous studies on
age-associated global DNA methylation have reported age-
dependent decrease in methylation based on adult to old
age populations. In addition, there are also reports of age-
associated increase in methylation [7] and methylation in-
creases in the early years of life [16]. Moreover, while many
loci such as intergenic CpGs outside of CpG islands
display decreased methylation in later life, other loci
such as promoter-associated CpG islands show increased
methylation with age throughout the lifespan [8]. There-
fore, in general global methylation decreases in old
age, it has not been established that this decrease oc-
curs continuously throughout life. Indeed, a general
increase in DNA methylation with age before adult-
hood, followed by stabilization and an eventual de-
crease in old age, has emerged from studies on different
age ranges using different methods [8]. The lifelong profile
obtained in the present study is consistent with this
general description, with the more comprehensive time
curve revealing a second period of methylation increase in
late middle-age prior to the methylation decline in old
age.
Significant difference between male and female sub-
jects was observed only in the late middle-age age group,
suggesting that gender-related factors may contribute to
this second period of methylation increase. The profile
of global methylation variation between genders is some-
what unclear with previous reports of significant differ-
ence based on methylation levels in LINE-1 repeat
elements for a 45–75 age group [17] but no difference
for a 19–80 age group [18] and no significant difference
based on the LUMA method for CCGG sites for a group
with mean age of 24 [19]. The different results suggest
that gender differences in “global” methylation levels are
dependent on age as well as the subset of methylation
sites examined in the quantification method.
DNA hypomethylation at old age has been reported in
studies focused on a relatively limited number of gene loci
and narrow age ranges, suggesting the possible associ-
ation between DNA methylation and age-related dis-
eases [9, 20, 21]. Indeed, the loss of global DNA
methylation is one of the first epigenetic abnormalities in
cancers [6], and advanced age represents a potent risk fac-
tor for human epithelial cancers with cancer incidence in-
creasing sharply from age 60 onward, especially in
males [22], which is in accord with the sharp de-
crease in DNA methylation over this age range shown
in Fig. 1. Likewise, evidence of age-associated loss of
DNA methylation in brain tissue suggests the signifi-
cant role of DNA hypomethylation at old age in the
pathogenesis of Alzheimer’s disease [23]. The onset of
Alzheimer’s disease at age 65 is also in accord with
the sharp decrease in global DNA methylation be-
tween the ages 55–70 shown in Fig. 1.
Unlike neurodegenerative and aging-related disorders,
neurodevelopmental disorders such as autism and Down
syndrome affect subject groups on the opposite end of the
age spectrum. Autism is highly heritable and affects infor-
mation processing in the brain, leading to symptoms that
include impairments in social interaction and communica-
tion, restricted interest, and repetitive behavior [24]. These
Fig. 2 Variation of global DNA methylation in autistic children. The
box plot shows methylation levels in healthy children (black) and
autistic children (red). The horizontal line in each box indicates the
median; the upper and lower bounds of the box represent the 75th
and 25th percentiles, respectively; the upper and lower whiskers for
each box mark the 95th and 5th percentiles, respectively; and the
squares indicate the maximum and minimum values. Double asterisk
indicates p < 0.001 for the pairwise comparison under the
independent sample t test
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characteristic symptoms become apparent in early child-
hood, typically before the age of three. Although the eti-
ology of autism is mainly ascribed to genetic variations
including single nucleotide polymorphisms and copy num-
ber variations [25], epigenetic mechanisms have been in-
voked to affect the environmental influences [4, 26]. As
such, DNA methylation has been associated with dysregu-
lation of biological pathways in autistic brains, with both
hypomethylated and hypermethylated genomic regions be-
ing identified [5]. Recently, in peripheral blood analysis,
the OXTR promoter was shown to be hypomethylated in
autism cases [27]. Here, we have demonstrated that the
global methylation in autistic children was increased com-
pared to healthy children (Fig. 2) with respect to the over-
all effect across all CCGG sites recognized by the HpaII/
MspI enzymes, encompassing both hypermethylated and
hypomethylated sites as well as unchanged sites. The over-
all increase suggests that hypermethylated regions were
more extensive than hypomethylated regions in the autis-
tic genome. Moreover, in comparison with the time profile
for methylation, the higher methylation level is that ex-
pected of young to middle-aged adults and this could be
interpreted to suggest an abnormally advanced methylome
in autistic children. This is reflected in that no significant
difference in methylation was found between autistic chil-
dren and their parents. From another point of view, since
a general increase in methylation takes place from young
to middle age (Fig. 1), the comparison between children
and parents is confounded by the age factor, and the result
demonstrates the importance of using age-matched con-
trols in analyzing methylation differences. Notably, envir-
onmental and nutritional factors may also affect
methylation, and application of the FPDM method will fa-
cilitate the in-depth analysis of the quantitative effects of
such external factors.
In conclusion, global DNA methylation measurements
in the present study on leukocyte DNA have shown a
multiphasic variation with age that leads to depression of
methylation at old age to half its level at middle age,
thereby providing strong evidence for DNA hypomethyla-
tion at old age as a potent risk marker for various age-
related disorders such as cancers, cardiovascular and neu-
rodegenerative disorders, and type 2 diabetes. In contrast,
hypermethylation was observed for autism, a neuro-
developmental condition. These measurements, read-
ily performed with the FPDM method, provide a
simple and quantitative approach to investigate the
multiple genetic and environment factors that deter-
mine global DNA methylation. A delineation of glo-
bal methylation changes will complement studies on
gene-specific methylation changes to yield an increas-
ingly comprehensive understanding of the regulation of
DNA methylation and the roles of DNA methylation in
age-related diseases.
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